Research
Hormonal
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists improve metabolic health in obesity and type 2 diabetes by lowering BMI, improving insulin sensitivity, and potentially activating thermogenic fat.
GLP-1 and GLP-1/GIP agonists are powerful tools for treating obesity and type 2 diabetes. They work by reducing appetite and improving how your body handles insulin and fat. These drugs have been shown to lead to significant weight loss (over 20% in some cases) and improve heart health. They are often used alongside lifestyle changes like diet and exercise.
StrongSupportsVERY_HIGH confidence
GLP-1 receptor agonists have been associated with favorable metabolic changes in obese human subjects such as lowering of BMI, improved ability of insulin to suppress lipolysis and hepatic glucose production, and reduction in hepatic steatosis... Prolonged treatment with GLP-1 receptor agonists have also been reported to activate thermogenic fat in humans.
Why this rating
Cites multiple randomized controlled trials and FDA approvals.
Source
Adipose Tissue and Metabolic Health
Sung‐Min An et al. · Diabetes & Metabolism Journal · 2023
DOI 10.4093/dmj.2023.0011
narrative_reviewCited 136×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Visceral adipose tissue accumulation is a primary risk factor for cardiometabolic disease, whereas subcutaneous fat is metabolically neutral or healthy.Strong
- Pharmacological activation of brown and beige adipose tissue thermogenesis via beta-3 adrenergic signaling or UCP1-independent futile cycles increases energy expenditure and improves systemic metabolic health.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →